Eventide Asset Management CSTL Position
Active3-Fund ConvergenceEventide Asset Management initiated a new position in CASTLE BIOSCIENCES INC (CSTL) in Q4 2025, holding $11.9M worth of shares across 305,000 shares.
CSTL is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for D-Fi in 532 days (Sep 30, 2027), making the timing of Eventide's position particularly relevant.
About CASTLE BIOSCIENCES INC
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Full company profile →Short Interest
5.5%
3.3 days to cover
Frequently Asked Questions
Does Eventide Asset Management own CSTL?
Yes. As of Q4 2025, Eventide Asset Management holds 305,000 shares of CASTLE BIOSCIENCES INC (CSTL) valued at $11.9M. This data comes from their SEC 13F filing.
How many hedge funds own CSTL?
3 specialist biotech hedge funds currently hold CSTL, including RTW Investments, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy CSTL?
Eventide Asset Management's position in CSTL was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's CSTL position increasing or decreasing?
Eventide Asset Management initiated a new position in CSTL in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CSTLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →